Literature DB >> 10449698

L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery.

I Schulze-Neick1, D J Penny, M L Rigby, C Morgan, A Kelleher, P Collins, J Li, A Bush, E A Shinebourne, A N Redington.   

Abstract

BACKGROUND: The increase in pulmonary vascular resistance (PVR) seen in children after cardiopulmonary bypass has been attributed to transient pulmonary endothelial dysfunction (PED). We therefore examined PED in children with congenital heart disease by assessing the L-arginine-nitric oxide (NO) pathway in terms of substrate supplementation (L-arginine [L-Arg]), stimulation of endogenous NO release (substance P [Sub-P]), and end-product provision (inhaled NO) before and after open heart surgery. METHODS AND
RESULTS: Ten patients (aged 0.62+/-0.27 years) with pulmonary hypertension undergoing cardiac catheterization who had not had surgery and 10 patients (aged 0.65+/-0.73 years) who had recently undergone cardiopulmonary bypass were examined. All were sedated and paralyzed and received positive-pressure ventilation. Blood samples and pressure measurements were taken from catheters in the pulmonary artery and the pulmonary vein or left atrium. Respiratory mass spectrometry was used to measure oxygen uptake, and cardiac output was determined by the direct Fick method. PVR was calculated during steady state at ventilation with room air, during FIO(2) of 0.65, then during additional intravenous infusion of L-Arg (15 mg. kg(-1). min(-1)) and Sub-P (1 pmol. kg(-1). min(-1)), and finally during inhalation of NO (20 ppm). In preoperative patients, the lack of an additional significant change of PVR with L-Arg, Sub-P, and inhaled NO suggests little preexisting PED. Postoperative PVR was higher, with an additional pulmonary endothelial contribution that was restorable with L-Arg and Sub-P.
CONCLUSIONS: Postoperatively, the rise in PVR suggested PED, which was restorable by L-Arg and Sub-P, with no additional effect of inhaled NO. These results may indicate important new treatment strategies for these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449698     DOI: 10.1161/01.cir.100.7.749

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 2.  Inhaled nitric oxide and related therapies.

Authors:  Frederick E Barr; Duncan Macrae
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

3.  Perioperative management of pulmonary hypertension in children with critical heart disease.

Authors:  Ronald A Bronicki
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

4.  Personalized genomic medicine: lessons from the exome.

Authors:  Benjamin D Solomon; Daniel E Pineda-Alvarez; Donald W Hadley; Jamie K Teer; Praveen F Cherukuri; Nancy F Hansen; Pedro Cruz; Alice C Young; Robert W Blakesley; Brendan Lanpher; Stephanie Mayfield Gibson; Murat Sincan; Settara C Chandrasekharappa; James C Mullikin
Journal:  Mol Genet Metab       Date:  2011-07-05       Impact factor: 4.797

5.  Genetic variation in the mitochondrial enzyme carbamyl-phosphate synthetase I predisposes children to increased pulmonary artery pressure following surgical repair of congenital heart defects: a validated genetic association study.

Authors:  Jeffrey A Canter; Marshall L Summar; Heidi B Smith; Geraldine D Rice; Lynn D Hall; Marylyn D Ritchie; Alison A Motsinger; Karla G Christian; Davis C Drinkwater; Frank G Scholl; Karrie L Dyer; Ann L Kavanaugh-McHugh; Frederick E Barr
Journal:  Mitochondrion       Date:  2006-11-29       Impact factor: 4.160

6.  Rescue Treatment with L-Citrulline Inhibits Hypoxia-Induced Pulmonary Hypertension in Newborn Pigs.

Authors:  Candice D Fike; Anna Dikalova; Mark R Kaplowitz; Gary Cunningham; Marshall Summar; Judy L Aschner
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

Review 7.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

8.  Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.

Authors:  Christian Stocker; Daniel J Penny; Christian P Brizard; Andrew D Cochrane; Rodrigo Soto; Lara S Shekerdemian
Journal:  Intensive Care Med       Date:  2003-10-07       Impact factor: 17.440

9.  Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years--a revisit.

Authors:  Jennifer Rutledge; Andrew Bush; Lara Shekerdemian; Ingram Schulze-Neick; Daniel Penny; Sally Cai; Jia Li
Journal:  Am Heart J       Date:  2010-07       Impact factor: 4.749

10.  Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases.

Authors:  Xi Zhang; Hai-Tao Hou; Jun Wang; Xiao-Cheng Liu; Qin Yang; Guo-Wei He
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.